Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness

Stanford University

Status

Not yet enrolling

Conditions

Psychotropic Agents Causing Adverse Effects in Therapeutic Use

Bipolar Disorder, Type 1

Bipolar Disorder

Obesity

Metabolic Syndrome

Bipolar Disorder, Mixed

Bipolar II Disorder

Bipolar Disorder I

Weight Gain

Bipolar I Disorder

Bipolar and Related Disorders

Bipolar Depression

Brain Metabolic Disorder

Ketogenic Dieting

Bipolar Disorder, Type 2

Treatments

Other: LCHF Ketogenic Diet

Study type

Interventional

Funder types

Other

Identifiers

NCT05705063

68493

Details and patient eligibility

About

To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking psychotropic medications experiencing metabolic side effects.

Full description

Adults with mental illness represent a high-risk, marginalized group in the current metabolic and obesity epidemic. Among US adults with severe mental illness, metabolic syndrome are highly prevalent conditions having severe consequences, with patients estimated to die on average 25 years earlier than the general population largely of premature cardiovascular disease. Many psychiatric medications, particularly neuroleptics and mood stabilizers, may, in addition, contribute to metabolic side effects and weight gain. Low-carbohydrate high-fat (LCHF) or ketogenic diets (KD) have been shown to reduce cardiovascular risk in those with insulin resistance. Recent findings support the idea that bipolar disorder may have roots of metabolic dysfunction: cerebral glucose hypometabolism, oxidative stress, as well as mitochondrial and neurotransmitter dysfunction which has downstream effects on synapse connections. A KD diet provides alternative fuel to the brain aside from glucose and is believed to contain beneficial neuroprotective effects, including stabilization of brain networks, reduction of inflammation and oxidative stress. The purpose of this study is to evaluate both the metabolic and psychiatric outcomes with a KD diet in this psychiatric population.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female, 18 to 75 years of age.
Able to provide informed consent.
Meet DSM V criteria for diagnosis with Bipolar Disorder (BPD), any subtype, for > 1 year and clinically stable (with no hospitalization for past 3 months)
Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy or other psychiatric medications. Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable. Participants may choose to not be on antidepressant therapy for the study duration, or to be switched from other classes to a medication from the SSRI class.
currently taking SSRI or psychotropic medication and gained at least 5% weight since starting medication or have a BMI greater than or equal to 26 kg/m2 or presence of at least one metabolic abnormality (hypertriglyceridemia, insulin resistance, dyslipidemia, impaired glucose tolerance)
In good general health, as ascertained by medical history.
If female, a status of non-childbearing potential or use of an acceptable form of birth control. The form of birth control will be documented at screening and baseline.
willing to consent to all study procedures and attend follow-up appointments and motivated to follow dietary program.
Sufficient control over their food intake to adhere to study diets.
willingness to regularly monitor blood pressure, glucose, dietary intake, and body weight over 6-week trial

Exclusion criteria

Female of childbearing potential who is not willing to use one of the specified forms of birth control during the study.
Female that is pregnant or breastfeeding.
Female with a positive pregnancy test at participation.
comorbidity of developmental delay or Cognitive impairment (as noted by previous diagnoses-including dementia).
Current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine dependence, at screening or within six months prior to screening.
History of positive screening urine test for drugs of abuse at screening: cocaine, amphetamines, barbiturates, opiates.
Current (or chronic) use of opiates.
in a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary program.
Considered at significant risk for suicide during the course of the study.
any one who has been hospitalized or taken clozapine at doses above 550mg over the past 3 months
Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results.
Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation.
inability to complete baseline measurements
severe renal or hepatic insufficiency
cardiovascular dysfunction, including diagnosis of:
1. Congestive heart failure
2. Angina
3. Arrhythmias
4. Cardiomyopathy
5. Valvular heart disease
6. History of cardiovascular disease or cardiac event.
any other medical condition that may make either diet dangerous as determined by the study medical team (e.g. anorexia nervosa)